Idelalisib (also known as CAL-101, GS-1101, IC489666, Zydelig) is a potent and selective inhibitor of highly specific small-molecule phosphatidylinositol-3-kinase (PI3Kδ), which mediates B-cell receptor (BCR) signaling and microenvironmental support signals that promote the growth and survival of malignant B lymphocytes. It has been reported that idelalisib induces apoptosis and inhibits proliferation in cell lines derived from malignant B lymphocytes and in primary tumor cells. Recently, idelalisib has been approved for the treatment of several hematological malignancies.
Exploiting the PI3K/AKT pathway for cancer drug discovery.
Taming the PI3K team to hold inflammation and cancer at bay.
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
B-cell receptor signaling as a driver of lymphoma development and evolution.
Haematological cancer: Idelalisib—targeting PI3Kδ in patients with B-cell malignancies.